SCHEMBL5758181

SCHEMBL5758181

Cc1cccc(-n2c(C)ccc(C(=O)NCc3cccc(Cl)c3)c2=O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.54
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
HCRTR1 O43613 1/20 0.48
APEX1 P27695 1/20 0.47
PDE10A Q9Y233 1/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CCR1 P32246 2/20 0.46
PTGER1 P34995 1/20 0.45
NPC1 O15118 1/20 0.45
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.43
LMNA P02545 1/20 0.43
F2 P00734 1/20 0.43
PRSS1 P07477 1/20 0.43
PRSS2 P07478 1/20 0.43
PRSS3 P35030 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5758113 0.96 ELANE (0.57) ELANEKMT2AMEN1HCRTR1APEX1
SCHEMBL6215308 0.92 RXFP1 (0.52) ELANEKMT2AAPEX1PDE10AKDM4E
SCHEMBL5756619 0.90 ELANE (0.60) ELANEKMT2AMEN1KDM4EHPGD
SCHEMBL5757167 0.89 MAPT (0.53) ELANEKMT2AMEN1APEX1PDE10A
SCHEMBL5756974 0.88 ELANE (0.62) ELANEKMT2AMEN1HPGDCCR1
SCHEMBL5761301 0.88 ELANE (0.70) ELANEKMT2AMEN1HPGDCCR1
SCHEMBL5757342 0.87 ELANE (0.50) ELANEKMT2AMEN1HCRTR1APEX1
SCHEMBL6212506 0.85 TP53 (0.55) ELANEKMT2AMEN1APEX1PDE10A
SCHEMBL5756649 0.85 KMT2A (0.46) ELANEKMT2AMEN1HCRTR1APEX1
SCHEMBL5759832 0.84 ELANE (0.58) ELANEKMT2AMEN1APEX1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 ELANE 2/4885KMT2A 4487/4885MEN1 3423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.